PSDZDATA FULL 56.2 UPDATE

PSDZDATA FULL 56.2 UPDATE

We also continue to advance our pipeline of product candidates with CPI-0209 and the newly announced CPI-482.РІР‚СњР”В¬onstellation presented an update of MANIFEST data in two oral presentations and three posters at the American Society of Hematology 2020 Annual Meeting, which are available on ConstellationРІР‚в„ўs website. РІР‚СљWe are executing on our recently launched Phase 3 trial, MANIFEST-2 and believe pelabresib has the potential to transform the standard of care in myelofibrosis. РІР‚Сљ2020 was an important year for Constellation Pharmaceuticals, marked by several presentations of strong data from our MANIFEST clinical trial for pelabresib (formerly CPI-0610), including our oral presentations at the ASH Annual Meeting,РІР‚Сњ said Jigar Raythatha, President and Chief Executive Officer of Constellation Pharmaceuticals. 24, 2021 (GLOBE NEWSWIRE) - Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter 2020 financial results and provided a business update.

Psdzdata full 56.2